SOURCE-LINKED STUDY SUMMARY
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized trial comparing semaglutide with placebo for major cardiovascular events.
- Who / model studied
- 17,604 adults aged 45 or older with cardiovascular disease and overweight or obesity, without diabetes; average follow-up was 39.8 months.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The primary combined outcome—cardiovascular death, nonfatal heart attack or nonfatal stroke—occurred in 6.5% with semaglutide versus 8.0% with placebo. Adverse events led 16.6% versus 8.2% to permanently stop treatment.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2307563